Clinical Trial

Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study explores how stress, suicidal thoughts, and ketamine's effects are connected in people with major depressive disorder. Stress increases the risk for suicidal thoughts, but the biological basis is unclear. Ketamine may help reduce suicidal thoughts by affecting stress-linked brain systems. This study will use smartphone tracking to monitor real-time responses to stress and positron emission tomography (PET) brain scans to study how ketamine affects brain pathways related to stress and suicidal thoughts in depressed individuals.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2028-05-01 -> 2028-10-01 2026-08-04
minor Completion pushed: 2028-05-01 -> 2028-10-01 2026-08-04
Trial Details
NCT Number NCT07139106
Lead Sponsor New York State Psychiatric Institute
Collaborators: American Foundation for Suicide Prevention
Conditions Major Depressive Disorder (MDD)
Enrollment 12 participants
Start Date 2026-10-01
Primary Completion 2028-10-01 (estimated)
Study Completion 2028-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-03